Cognition Therapeutics (CGTX) News Today → The 2024 Gold Rush: Unleashing Market Potential (From Priority Gold) (Ad) Free CGTX Stock Alerts $2.00 +0.08 (+4.17%) (As of 05/8/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineCognition Therapeutics, Inc.: Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Updatefinanznachrichten.de - May 7 at 12:34 PMCognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Updatemarkets.businessinsider.com - May 7 at 12:34 PMCognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Updateglobenewswire.com - May 7 at 7:30 AMCognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodiesfinance.yahoo.com - April 29 at 10:01 AMCognition Therapeutics, Inc. (NASDAQ:CGTX) Short Interest Updatemarketbeat.com - April 27 at 8:39 PMCognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Diseasefinance.yahoo.com - April 22 at 9:01 AMCognition Therapeutics, Inc. (NASDAQ:CGTX) Sees Large Drop in Short Interestmarketbeat.com - April 12 at 8:36 PMCognition Therapeutics to Present at the Needham Virtual Healthcare Conferenceglobenewswire.com - April 2 at 7:30 AMCognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer’s Disease on April 12, 2024finance.yahoo.com - April 1 at 8:24 AMCognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer's Disease on April 12, 2024globenewswire.com - April 1 at 7:30 AMBuy Rating Affirmed for Cognition Therapeutics Amid Promising CT1812 Clinical Trialsmarkets.businessinsider.com - March 28 at 7:24 PMB. Riley Reiterates "Buy" Rating for Cognition Therapeutics (NASDAQ:CGTX)marketbeat.com - March 28 at 12:33 PMCognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 27 at 10:06 AMCognition Therapeutics (NASDAQ:CGTX) Rating Reiterated by Oppenheimermarketbeat.com - March 27 at 8:29 AMCognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Updateglobenewswire.com - March 26 at 7:00 AMA Preview Of Cognition Therapeutics's Earningsbenzinga.com - March 26 at 12:10 AMCognition Therapeutics, Inc. (NASDAQ:CGTX) Sees Significant Increase in Short Interestmarketbeat.com - March 15 at 3:13 PMCognition Therapeutics to Report Fourth Quarter and Full Year 2023 Resultsglobenewswire.com - March 15 at 7:30 AMCognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stockglobenewswire.com - March 14 at 4:05 PMCognition Therapeutics Prices Public Offering Of About 6.57 Mln Shares At $1.75/shrmarkets.businessinsider.com - March 12 at 2:27 AMCognition Therapeutics announces pricing of stock offering to raise $11.5Mmsn.com - March 12 at 2:27 AMGiants GM Joe Schoen swings big in trade, blockbuster contract for Panthers pass rusher Brian Burns while losing Xavier McKinneymsn.com - March 11 at 9:26 PMCognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stockglobenewswire.com - March 11 at 8:16 PMCognition Therapeutics Announces Proposed Public Offering of Common Stockglobenewswire.com - March 11 at 4:05 PMCognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studiesfinance.yahoo.com - March 6 at 4:22 PMCognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer's Disease Studiesglobenewswire.com - March 6 at 7:30 AMCognition Therapeutics to Present at the TD Cowen Health Care Conferenceglobenewswire.com - February 26 at 7:30 AMAnalysts Are Bullish on These Healthcare Stocks: Olema Pharmaceuticals (OLMA), IDEAYA Biosciences (IDYA)markets.businessinsider.com - February 22 at 2:04 PMCognition Therapeutics, Inc.: New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812finanznachrichten.de - February 6 at 2:12 PMNew Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812finance.yahoo.com - February 6 at 9:11 AMStudy suggests how cognitive behavioral therapy changes brain activity in children with anxietymsn.com - February 1 at 9:10 PMHere's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situationfinance.yahoo.com - January 16 at 2:48 PMDigital CBT intervention reduces anxiety and improves quality of life for pulmonary fibrosis patientsmsn.com - January 8 at 8:06 AMCognition Therapeutics, Inc.: Cognition Therapeutics CEO Issues Letter to Shareholdersfinanznachrichten.de - January 4 at 11:21 AMCognition Therapeutics CEO Issues Letter to Shareholdersfinance.yahoo.com - January 4 at 11:21 AMCognition Therapeutics files to sell 6.03M shares for holdersmsn.com - December 29 at 6:13 PMCognition Therapeutics Inc CGTXmorningstar.com - November 22 at 9:26 AMCognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltensfinance.yahoo.com - November 16 at 10:15 AMCognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer's and Parkinson's Diseasesstockhouse.com - November 15 at 1:13 PMCognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s Diseasesfinance.yahoo.com - November 15 at 8:13 AMCognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Diseasebenzinga.com - November 7 at 8:49 AMCognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Diseasefinance.yahoo.com - November 7 at 8:49 AMCognition Therapeutics Inc (CGTX) Reports Q3 2023 Financial Resultsfinance.yahoo.com - November 3 at 8:58 AMCognition Therapeutics GAAP EPS of $0.22 beats by $0.46msn.com - November 2 at 12:35 PMCognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - November 2 at 12:35 PMCognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer’s Disease at CTADfinance.yahoo.com - October 27 at 12:48 PMCognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease at CTADstockhouse.com - October 24 at 7:49 PMCognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at CTADfinance.yahoo.com - October 24 at 7:49 PMCognition Therapeutics Presents New Data at CTAD Conference from Advancing Pipeline Across Multiple CNS Indicationsfinance.yahoo.com - October 16 at 2:47 PMCognition Therapeutics Inc.thestreet.com - September 27 at 3:39 PM Get Cognition Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address AI “wealth window” is closing June 25th (Ad)Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry. I put together this personal video [HERE]… CGTX Media Mentions By Week CGTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CGTX News Sentiment▼-0.750.36▲Average Medical News Sentiment CGTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CGTX Articles This Week▼41▲CGTX Articles Average Week Get Cognition Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Athira Pharma News Today Precision BioSciences News Today Gritstone bio News Today Instil Bio News Today CEL-SCI News Today Passage Bio News Today Elutia News Today Atara Biotherapeutics News Today Protalix BioTherapeutics News Today SCYNEXIS News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CGTX) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressObama’s Forever Term [exposed]Porter & CompanyThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe ExchangeExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cognition Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
